Jun 08, 2022 9:46am EDT Wesana Health CEO Daniel Carcillo to Keynote Charles River Symposium: Re-Imagining Substance Abuse, Addiction, and Mental Health Disorders with Psychedelic Therapies
May 05, 2022 9:08am EDT Wesana Announces Singular Focus on Drug Development Prompting a Strategic Review of its Clinics and Other Care Delivery Assets
May 02, 2022 10:44pm EDT Wesana Health Reports Q4 2021 Financial Results and Provides Subsequent Period Highlights
Apr 18, 2022 6:34pm EDT Wesana Is Exploring Broadening SANA-013 Lead Indication to Treat Major Depressive Disorder
Mar 29, 2022 7:30am EDT Wesana Health CEO Daniel Carcillo to Speak at Several Leading Investor and Industry Events
Mar 22, 2022 7:30am EDT Wesana Health Announces New Findings Indicating Psilocybin Potentiates Impact of an Anti-Depressant
Mar 14, 2022 9:07am EDT Wesana Health Announces Positive Feedback From Pre-IND Meeting With FDA on SANA-013
